Shire considers new patent infringement suit from Watson on Adderall XR
This article was originally published in Scrip
Executive Summary
Shire has reported that two of its subsidiaries have received a new paragraph IV notice letter from Watson Laboratories advising of the filing of an ANDA with the US FDA for a generic version of all approved strengths of Shire's attention deficit hyperactivity disorder (ADHD) drug, Adderall XR (mixed salts of amphetamine).